WOBURN, Mass.–SRU Biosystems, a leader in label-free technologies, today announced that the Company has expanded its sales team with the addition of Senior Sales Executives Jane Clark and Rick Loomis to its North American division. Further, the Company announced the appointment of Steve Shamah, Ph.D., as its new Director of Cell Biology and member of the SRU management team.

“Coinciding with recent product introductions for the academic and uHTS markets, demand has significantly increased for the SRU BIND label-free technology,” said Mann Shoffner, Director of Sales and Marketing. “Further, there has been expanded interest in our platform for cell-based assays, including primary screening for uHTS in a 1536-well format. To meet this ramp, we have hired two outstanding sales executives to grow our outreach into North America. Both Jane and Rick have extensive sales and managerial experience in laboratory instrumentation, and we look forward to their guidance and leadership as we turn this next transition of expanded market penetration for SRU. Further, these hires allow us to further focus our efforts in Europe, where we have seen strong demand for the BIND technology.”

”In addition to our new additions to the sales team, we are also very fortunate to welcome Steve Shamah to SRU as our new Director of Cell Biology,” said Richard W. Wagner, Ph.D., President and CEO. “Steve will work with our cell biology applications group to continue to pioneer new applications and products using our label-free technology. Label-free technologies have proven to be important for understanding complicated pathways for GPCRs and ligand gated ion channels. Further, SRU’s recently enhanced BIND Reader product line and higher density consumables have enabled label-free to reach a whole new market of academic and uHTS users. Steve’s extensive knowledge of the needs of these users allows SRU to better develop applications and products that meet their unique needs. “

Jane Clark was most recently Senior Sales executive with VisEn Medical, Inc., and prior to that she held sales positions at Amaxa, Inc., Affymetrix, Inc., and Life Technologies, Inc. Rick Loomis most recently was Director, Industrial Sales at Lonza, and prior to that held sales and managerial positions at Genetix, Acea, and Perkin Elmer. Steve Shamah, Ph.D., was most recently Senior Principal Investigator at Archemix, Inc., and prior to that worked in the HTS group at Hydra Biosciences, Inc., and the cell biology group at Phylos, Inc.

SRU Biosystems’ label-free BIND® technology has extraordinary sensitivity and application flexibility. It can be used for complex cellular assays such as GPCR pathway analysis, ion channel assays and cell adhesion assays; as well as biochemical assays, such as protein:protein binding, enzyme assays, and fragment and small molecule screening. These applications have been utilized in exploring assay development, 1536-well high throughput screening, and lead profiling. SRU anticipates a continued expansion of its label-free BIND products, creating new assay capabilities.

About SRU Biosystems

SRU Biosystems, Inc., is a life science company offering novel, label-free tools used to answer important biological questions in biomedical research and pharmaceutical drug discovery. SRU’s label-free BIND® Technology can rapidly analyze the interactions of genomic, peptide, antibody or small molecule compound libraries against a wide range of cellular and biochemical targets. www.srubiosystems.com